← Back to Search

Anti-mitotic Agent

Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention (PacTAP Trial)

N/A
Waitlist Available
Led By Eric J Dippel, MD
Research Sponsored by Midwest Cardiovascular Research Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 and 12 months
Awards & highlights
Approved for 10 Other Conditions
All Individual Drugs Already Approved

Summary

The purpose of this study is to assess the safety and efficacy of administering intra-arterial paclitaxel in the femoropopliteal arteries via the TAPAS catheter following percutaneous revascularization to prevent restenosis.

Eligible Conditions
  • Peripheral Arterial Disease
  • Restenosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 and 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Primary Patency
Primary Safety
Secondary study objectives
Functional Status
Primary Assisted Patency
Primary Patency at 12 months
+2 more

Awards & Highlights

Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: PaclitaxelActive Control1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Midwest Cardiovascular Research FoundationLead Sponsor
5 Previous Clinical Trials
224 Total Patients Enrolled
3 Trials studying Peripheral Arterial Disease
136 Patients Enrolled for Peripheral Arterial Disease
Spectranetics CorporationIndustry Sponsor
25 Previous Clinical Trials
4,248 Total Patients Enrolled
16 Trials studying Peripheral Arterial Disease
3,975 Patients Enrolled for Peripheral Arterial Disease
Eric J Dippel, MDPrincipal InvestigatorMidwest Cardiovascular Research Foundation
1 Previous Clinical Trials
252 Total Patients Enrolled
1 Trials studying Peripheral Arterial Disease
252 Patients Enrolled for Peripheral Arterial Disease
~7 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top